INDFY yields 2.81% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, INDFY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of INDFY + JNJ for your $10,000?
Indofood Agri Resources Ltd., together with its subsidiaries, operates as a vertically integrated agribusiness company in Singapore, Indonesia, China, Nigeria, Timor Leste, Germany, the Philippines, Myanmar, and internationally. It engages in the research and development; oil palm seed breeding; oil palm cultivation and milling; crude palm oil production and refining; rubber, sugar cane, cocoa, and tea cultivation; and industrial timber plantation activities. The company operates in two segments, Plantations, and Edible Oils and Fats. The Plantations segment is involved in the development and maintenance of oil palm, rubber, and sugar cane plantations; and other business activities relating to processing, marketing, and selling palm oil, rubber, and sugar cane. The Edible Oils and Fats segment produces, markets, and sells edible oil, margarine, shortening, and other related products, as well as its derivative products. It offers cooking oil under the Bimoli, Bimoli Spesial, Delima, Amanda, and Happy brands; and margarine and shortening products under the Amanda, Palmia, Royal Palmia, Simas, Malinda, and Delima brands. As of December 31, 2021, the company had a planted area of approximately 300,749 hectares, including 250,615 hectares of oil palm; 16,228 hectares of rubber; 14,411 hectares of sugar cane; and 19,495 hectares of other crops. It also owns and operates bulking facilities; provides transportation, investment, management, and technical services; and operates in the macronutrients mix fertilizers and prefabrication industries. The company was incorporated in 2001 and is headquartered in Singapore. Indofood Agri Resources Ltd. is a subsidiary of Indofood Singapore Holdings Pte. Ltd.
Full INDFY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.